Gan & Lee Insulins Data Is Boon For Sandoz
Three Biosimilar Candidates Meet Primary Analyses
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.
You may also be interested in...
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
A strong case exists for a more tailored approach to biosimilars development that could increase regulatory efficiency and broaden access, Sandoz’s head of biopharmaceuticals, Pierre Bourdage, tells Generics Bulletin in an exclusive interview.